Biweekly Capecitabine Schedule Feasible

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 7
Volume 16
Issue 7

A biweekly dosing regimen of capecitabine (Xeloda) was well tolerated in a dose-escalation study of metastatic breast cancer patients, allowing safe delivery of higher daily doses than routinely used in practice

ASCO—A biweekly dosing regimen of capecitabine (Xeloda) was well tolerated in a dose-escalation study of metastatic breast cancer patients, allowing safe delivery of higher daily doses than routinely used in practice, Maria Theodoulou, MD, Memorial Sloan-Kettering Cancer Center, reported at the ASCO 2007 meeting (abstract 1045). Capecitabine is typically delivered on a 14-days-on/7-days-off schedule at 1,250 mg/m2 twice daily (total of 2,500 mg/m2/d). In the current study, the agent was given on a 7-days-on/7-days-off schedule with a maximum tolerated dose of 2,000 mg/m2 twice daily (total of 4,000 mg/m2/d).

The design of the single-center, open-label, phase I/II study was based on Norton-Simon mathematical modeling that predicted the optimal dosing schedule for capecitabine. There were no grade 4-5 toxicities, and grade 3 toxicities were transient and manageable. "This new dosing regimen for capecitabine will serve as a platform for combination treatment with targeted therapies," said lead author Clifford Hudis, MD, chief of the Breast Cancer Medicine Service.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Related Content